The Schwann cell-specific G-protein Gαo (Gnao1) is a cell-intrinsic controller contributing to the regulation of myelination in peripheral nerve system

• Published in: Acta neuropathologica communications 2024-02, Vol.12 (1), p.24-24, Article 24
• Main Authors: Xu, Jinghui, Peng, Qianqian, Cai, Jieyi, Shangguan, Jianghong, Su, Wenfeng, Chen, Gang, Sun, Hualin, Zhu, Changlai, Gu, Yun
• Format: Article
• Language: English
• Subjects: (Re-)myelination; Animals; Convulsions & seizures; Cyclic AMP; Demyelinating diseases; Differentiation; Fibroblasts; Gnao1; GTP-Binding Proteins; Guillain-Barre syndrome; Kinases; Laboratory animals; Mammals - metabolism; Mice; Mutation; Myelin Sheath - metabolism; Nervous system; Neurological disorders; Peripheral Nervous System - metabolism; Phosphatidylinositol 3-Kinases; Proteins; Proto-Oncogene Proteins c-akt - metabolism; Schwann Cells; Viruses
• ISSN: 2051-5960; 2051-5960
• DOI: 10.1186/s40478-024-01720-3

Myelin sheath abnormality is the cause of various neurodegenerative diseases (NDDs). G-proteins and their coupled receptors (GPCRs) play the important roles in myelination. Gnao1, encoding the major Gα protein (Gαo) in mammalian nerve system, is required for normal motor function. Here, we show that Gnao1 restricted to Schwann cell (SCs) lineage, but not neurons, negatively regulate SC differentiation, myelination, as well as re-myelination in peripheral nervous system (PNS). Mice lacking Gnao1 expression in SCs exhibit faster re-myelination and motor function recovery after nerve injury. Conversely, mice with Gnao1 overexpression in SCs display the insufficient myelinating capacity and delayed re-myelination. In vitro, Gnao1 deletion in SCs promotes SC differentiation. We found that Gnao1 knockdown in SCs resulting in the elevation of cAMP content and the activation of PI3K/AKT pathway, both associated with SC differentiation. The analysis of RNA sequencing data further evidenced that Gnao1 deletion cause the increased expression of myelin-related molecules and activation of regulatory pathways. Taken together, our data indicate that Gnao1 negatively regulated SC differentiation by reducing cAMP level and inhibiting PI3K-AKT cascade activation, identifying a novel drug target for the treatment of demyelinating diseases.